Starting July 1, Medicare will cover semaglutide for weight loss in eligible beneficiaries with cardiovascular disease, a policy shift that could dramatically increase the number of patients using this GLP-1 receptor agonist. While the move addresses a critical need for obesity treatment, it also intensifies a long-standing concern in metabolic research: the loss of lean body mass that often accompanies pharmacologically driven weight reduction. In clinical trials, semaglutide has been shown to produce substantial weight loss, but a portion of that loss consistently comes from muscle tissue. This has prompted investigators to explore adjunctive compounds that might shift the balance toward fat loss while sparing muscle. One such compound under study is AOD-9604, a peptide fragment of human growth hormone that has demonstrated lipolytic and muscle-preserving properties in preclinical models. This article examines the research landscape for AOD-9604 as a potential complement to semaglutide, with a focus on what published studies can and cannot tell us at this stage. Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.
The expanded Medicare coverage, announced in March 2024, applies to semaglutide (Wegovy) for patients with obesity and established cardiovascular disease. This decision follows the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in participants taking semaglutide. However, the same trial reported that approximately 40% of the weight lost was lean mass, a finding consistent with other GLP-1 agonist studies. For older adults, who are already at risk for sarcopenia, this muscle loss could have functional consequences. Researchers have therefore begun looking for interventions that could be used alongside semaglutide to mitigate these effects. AOD-9604, a modified fragment of growth hormone (amino acids 177-191), has attracted attention because it appears to stimulate lipolysis without the diabetogenic effects of full-length growth hormone. Preclinical studies suggest it may also promote muscle protein synthesis, though human data remain limited.
AOD-9604 was originally developed as an anti-obesity agent. Early human trials in the early 2000s tested its safety and efficacy for weight loss, with mixed results. A 2007 phase 2b trial found that AOD-9604 did not achieve significant weight loss compared to placebo over 12 weeks, and development for obesity was largely halted. However, subsequent research has focused on its potential for targeted fat reduction and muscle preservation. A 2014 study in mice fed a high-fat diet showed that AOD-9604 reduced fat mass while preserving lean mass, an effect not seen with caloric restriction alone (PubMed). More recently, a 2022 in vitro study demonstrated that AOD-9604 promoted myoblast differentiation and reduced dexamethasone-induced muscle atrophy, suggesting a direct effect on muscle cells (PubMed). These findings have led to speculation that AOD-9604 could be paired with GLP-1 agonists to counteract muscle loss, but no clinical trials have tested this combination. This is a 2 of 3 on evidence quality: the mechanistic data are compelling, but the absence of human combination studies is a significant gap.
The muscle-sparing properties of AOD-9604 are thought to stem from its ability to activate the growth hormone receptor in a selective manner. Unlike full-length growth hormone, which can raise blood glucose and cause insulin resistance, AOD-9604 does not appear to affect glucose metabolism. A 2019 study in rats confirmed that AOD-9604 increased fat oxidation without altering insulin sensitivity (PubMed). This is particularly relevant for patients on semaglutide, which already improves glycemic control. Theoretically, adding AOD-9604 could enhance fat loss while protecting muscle, but this hypothesis has not been tested in humans. Outcomes described in studies cited here cannot be assumed to generalise to individual users. Other peptides are also being investigated for muscle preservation during weight loss. Tesamorelin, a growth hormone-releasing hormone analog, has been shown to reduce visceral fat and preserve lean mass in HIV patients with lipodystrophy, but its effects in obesity are less clear. MOTS-c, a mitochondrial-derived peptide, has demonstrated metabolic benefits in mice, including increased muscle glucose uptake, but human data are sparse. Retatrutide, a triple agonist (GLP-1, GIP, glucagon), is in phase 3 trials and has shown greater weight loss than semaglutide, but its impact on body composition is still being evaluated. For now, AOD-9604 remains one of the more studied peptides in the context of muscle sparing, albeit with significant limitations.
One of the challenges in evaluating AOD-9604 is the lack of standardized dosing and administration protocols. In the 2007 trial, participants received 1 mg daily via subcutaneous injection, but optimal dosing for muscle preservation is unknown. The peptide has a short half-life, which may limit its efficacy without frequent dosing. Researchers have also raised questions about its stability and bioavailability. A 2021 review noted that while AOD-9604 is generally well-tolerated, its effects on body composition are modest and inconsistent across studies (PubMed). This is a 1 of 3 on evidence quality for muscle-sparing claims: the human data are weak, and most positive findings come from animal or cell models. For patients and clinicians, the key question is whether the potential benefits justify the unknowns. The Medicare coverage expansion will likely increase semaglutide use, making this question more urgent. However, without robust clinical trials, any discussion of AOD-9604 as a muscle-sparing agent remains speculative. This is an editorial discussion of published research. It is not a treatment plan.
Another consideration is the regulatory status of AOD-9604. It is not approved by the FDA for any indication, and it is often sold as a research chemical or dietary supplement. This raises concerns about quality control and safety. A 2023 analysis of peptide products purchased online found that many contained impurities or incorrect dosages (PubMed). For researchers, this underscores the need for pharmaceutical-grade compounds in future studies. The combination of semaglutide and AOD-9604 has not been evaluated in any published trial, so potential interactions are unknown. Given that both compounds can affect metabolism, there is a theoretical risk of hypoglycemia or other adverse effects. Until such studies are conducted, the use of AOD-9604 alongside semaglutide cannot be recommended outside of a research setting.
The Medicare policy shift also highlights the broader issue of body composition during weight loss. While semaglutide and other GLP-1 agonists are effective for weight reduction, they do not discriminate between fat and muscle. This has led to interest in adjunctive therapies that could improve the quality of weight loss. AOD-9604 is one candidate, but others include resistance exercise, higher protein intake, and emerging peptides like BPC-157. A 2022 study in older adults with obesity found that combining a GLP-1 agonist with resistance training preserved lean mass better than the drug alone (PubMed). This suggests that non-pharmacological strategies may be equally important. For researchers, the challenge is to identify which interventions are most effective and for whom. The muscle loss seen with semaglutide is not inevitable, but it requires a proactive approach. As the research on combining AOD-9604 with semaglutide continues, the focus should remain on rigorous, controlled studies.
Looking ahead, several clinical trials are planned or underway that may shed light on muscle-sparing strategies. A phase 2 trial of bimagrumab, a monoclonal antibody that blocks activin type II receptors, is testing whether it can preserve muscle during semaglutide-induced weight loss. Results are expected in 2025. Another trial is evaluating the effects of a high-protein diet combined with semaglutide on body composition. AOD-9604 has not yet been included in such trials, but the growing interest in muscle health may prompt future investigations. The new ACP obesity guidelines emphasize the importance of preserving lean mass, which could drive funding for peptide research. For now, the evidence base for AOD-9604 is insufficient to draw firm conclusions. Researchers must address several open questions: What is the optimal dose and duration of AOD-9604 for muscle preservation? Does it interact with GLP-1 agonists in ways that affect safety or efficacy? And can it produce clinically meaningful improvements in body composition beyond what can be achieved with diet and exercise alone?